By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Intarcia Therapeutics, Inc. 

155 Seaport Boulevard
11th Floor
Boston  Massachusetts  02210  U.S.A.
Phone: 617-936-2500 Fax: n/a



Drug Discovery

Company News
Servier Bets $1 Billion+ On Intarcia Therapeutics, Inc.'s Diabetes Device 11/12/2014 6:12:53 AM
Boston's Intarcia Therapeutics, Inc. Touts Trial Results Of Potentially Revolutionary Type 2 Diabetes Treatment 10/2/2014 6:39:08 AM
Intarcia Therapeutics, Inc. Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 9/17/2014 8:58:43 AM
Intarcia Therapeutics, Inc. Announces Two Presentations At 50th EASD Meeting: Confirms Pivotal Phase 3 Data Announcement For ITCA 650 In Type 2 Diabetes In 4Q 9/12/2014 9:00:59 AM
Intarcia Therapeutics, Inc. Announces Appointment Of Dr. Sunita Zalani As Vice President, Global Head Of Regulatory Affairs And Quality 8/5/2014 9:26:37 AM
Intarcia Therapeutics, Inc. Release: Chairman & CEO Kurt Graves Presents First "Key Disruptor Award" To Tom Alessi, Ph.D., For His Innovations In Chemistry And Manufacturing That Transform Medicines For Patients 6/19/2014 10:02:27 AM
Intarcia Therapeutics, Inc.'s Once-A-Year Diabetes Drug ITCA 650 Impresses In Phase 3 Trial 6/16/2014 7:06:24 AM
Intarcia Therapeutics, Inc. Presents Interim Phase 3 Data At American Diabetes Association Showing ITCA 650, A Once Yearly GLP-1, Markedly Reduces Blood Sugar In Patients With Very Poorly Controlled Diabetes 6/16/2014 6:29:50 AM
Boston-Based Intarcia Therapeutics, Inc. Grabs $200 Million To Beef Up Pipeline 4/1/2014 7:24:14 AM
Intarcia Therapeutics, Inc. CEO To Present Company Progress, Interim Phase 3 Data, And Key Milestones At J.P. Morgan 1/13/2014 8:41:33 AM